It is interesting to observe that the board, the CFO Alistair Stevens, the CEO Matthys, and the company advisor Tim Day, of Sternship Advisers, have all been vocal to prospective providers of capital to the company that they wont be dealing with anyone connected to FW.
Raises issues surrounding whether shareholders best interests were being served given the debacle these guys have created by trying to eliminate and block FW as a competitor to their own so called recapitalisation process. No matter who the prospective bidders/ providers of capital are, one would have thought that competition would have resulted in better outcome for shareholders, growers and other stakeholders?
Secondly, shareholders should be wanting to know how Stevens, Day, and Matthys were to be incentivised regarding their own recapitalisation ambitions and how independent Day was as company advisor in this flawed process.
- Forums
- ASX - By Stock
- QIN
- Management and Advisor's Incentives
Management and Advisor's Incentives
-
-
- There are more pages in this discussion • 12 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add QIN (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online